Cargando…
Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
BACKGROUND: Bone metastases are common in women with breast cancer and often result in skeletal related events (SREs). As the angiogenic factor vascular endothelial growth factor (VEGF) regulates osteoclast activity and is associated with more extensive bone metastases and SRE risk in metastatic bre...
Autores principales: | Addison, Christina L., Pond, Gregory R., Cochrane, Brandy, Zhao, Huijun, Chia, Stephen K., Levine, Mark N., Clemons, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620970/ https://www.ncbi.nlm.nih.gov/pubmed/26579488 http://dx.doi.org/10.1016/j.jbo.2015.04.001 |
Ejemplares similares
-
Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial
por: Swaminath, Anand, et al.
Publicado: (2022) -
Vandetanib
por: Vozniak, J. Michael, et al.
Publicado: (2012) -
Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
por: Jáklová, Kateřina, et al.
Publicado: (2021) -
Stevens-Johnson Syndrome Induced by Vandetanib
por: Yoon, Jimi, et al.
Publicado: (2011) -
Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
por: Znati, Sami, et al.
Publicado: (2020)